Table 1.
Patient Information
| ||||
Age (years) | 57.5 | ± | 11.4 | |
Gender (female) | 29 | (71 %) | ||
Gender (Male) | 12 | (29%) | ||
Disease duration, years n=40 | 9.3 | ± | 8.4 | |
Early disease (<2 years), n= 40 | 9 | (23%) | ||
Positive Rheumatoid Factor (RF) n=40 | 23 | (58%) | ||
Positive Anti-CCP n=36 | 19 | (53%) | ||
ESR (mm/hour) n=14 | 33.5 | ± | 21.7 | |
DAS28 n=17 | 4.7 | ± | 1.3 | |
CDAI n=20 | 21.5 | ± | 10.6 | |
RAPID3 n=25 | 11.4 | ± | 7.4 | |
PGA n=24 | 4.7 | ± | 3.1 | |
HAQ n=18 | 0.7 | ± | 0.5 | |
TJC n=31 | 5.8 | ± | 6.0 | |
SJC n=31 | 7.1 | ± | 4.9 | |
Treatment (n=31) | ||||
no Treatment (naïve) | 3 | (10%) | ||
Methotrexate, current | 15 | (48%) | ||
Methotrexate, past | 9 | (29%) | ||
TNF-inhibitor, current | 12 | (38%) | ||
TNF-inhibitor, past | 17 | (55%) | ||
IL-6 inhibitor, current | 2 | (6%) | ||
IL-6 inhibitor, past | 2 | (6%) | ||
JAK-inhibitor, current | 3 | (10%) | ||
JAK-inhibitor, past | 5 | (16%) | ||
Other treatment, current | 11 | (35%) | ||
Other treatment, past | 12 | (39%) | ||
Prednisone, <5 mg, current | 1 | (3%) | ||
Prednisone, 5-10 mg, current | 6 | (19%) | ||
Histology-RA Synovial Biopsy (n=30) | ||||
% Synovial Tissue | 36.0 | ± | 5.6 | |
CD45 score (0-4) | 1.7 | ± | 0.2 | |
CD68 score (0-4) | 1 | ± | 0.1 | |
RNA-seq Stats | ||||
Whole Tissue Samples (RA=9, OA=9)
| ||||
RIN# | RA | 6.7 | ± | 0.5 |
OA | 8.0 | ± | 0.2 | |
# aligned reads (Million) | RA | 9.2 | ± | 0.7 |
OA | 12.9 | ± | 1.1 | |
% of total reads aligned | RA | 81 9 | ± | 1.2 |
OA | 85.3 | ± | 1.2 | |
% Complexity | RA | 54.8 | ± | 1.7 |
OA | 56.2 | ± | 1.9 | |
Sorted Macrophage Samples (RA=15, OA=9) | ||||
Cells sorted | RA | 1642 | ± | 1178 |
OA | 77414 | ± | 26413 | |
# aligned reads (Million) | RA | 21.0 | ± | 4.2 |
OA | 21.1 | ± | 6.8 | |
% of total reads aligned | RA | 53 9 | ± | 6.0 |
OA | 65.2 | ± | 1.5 | |
% Complexity | RA | 37.2 | ± | 2.7 |
OA | 38.1 | ± | 2.2 |